Table 1 The clinical and pathologic features of the ovarian fibrosarcoma cases examined
Reference | Case No. | Age | Symptom | FIGO stage | Largest diameter (cm) | Mitoses/10 HPFs | CD10 | Ki-67 (MIB-1) positive | Vimentin | CD117 | SMA | Des | EMA | S-100 | CD99 | CD34 | α-inhibin | ER | PR | CA125 U/ml | Therapy | Recurrence | Follow-up (months) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Interval (months) | Site | Treatment | |||||||||||||||||||||||
China Case 1[6] | 1 | 43 | AP | III c | 10 | ≥ 4 | (-) | 50%-75% | (+) | (-) | (-) | / | / | (-) | (-) | / | (-) | (-) | (-) | / | OR | 1 | Pelvis | BAO | Died (4) |
China Case 2 [7] | 2 | 39 | AP | I a | 11 | 5~7 | (-) | 85% | (+) | / | (-) | (-) | (-) | (-) | (-) | / | (-) | (-) | (-) | / | BAO | NP | NP | NP | TF (14) |
China Case 3 | 3 | 53 | NP | I a | 10 | 3~7 | / | / | (+) | / | (-) | (-) | (-) | (-) | (-) | / | (-) | (-) | (-) | 68.45 | BAO | NP | NP | NP | TF (12) |
China Case 4 | 4 | 20 | NP | II a | 7 | 3~5 | / | 15% | (+) | (-) | (-) | (-) | (-) | (-) | (-) | / | (-) | / | / | / | BAO | 6 | Pelvis | CT | Died (10) |
China Case 5[8] | 5 | 56 | NP | III c | 16 | 13 | (-) | 25% | (+) | (-) | (-) | (-) | (-) | (-) | (-) | (-) | / | / | / | < 35 | BAO+(IA+DTIC) | NP | NP | NP | TF (8) |
China Case 6[9] | 6 | 43 | NP | I a | 5.7 | 16 | (-) | > 10% | (+) | / | (-) | / | / | (-) | / | (-) | (+) | / | / | < 35 | BAO+PVB | NP | NP | NP | TF (7) |
China Case 7 [10] | 7 | 21 | AP | III b | 15 | ≥ 4 | / | > 10% | (+) | / | / | / | / | / | / | / | / | / | / | / | OR | 3 | Pelvis | NP | Died (6) |
China Case 8 | 8 | 66 | AP | II b | 11 | 8 | / | 15% | (+) | / | (-) | (-) | (-) | (-) | / | / | (-) | / | / | / | BAO | 10 | Sigmoid | SS+CT | Died (23) |
China Case 9 | 9 | 37 | AP | II c | / | ≥ 4 | (+) | 20% | (+) | (-) | (-) | (-) | (-) | (-) | / | (-) | (-) | (-) | (-) | 198 | BAO+(IA+DTIC) | NP | NP | NP | TF (15) |
China Case 10 | 10 | 44 | AP | III b | 13 | 23 | (-) | 75% | (+) | / | (-) | / | / | (-) | / | / | (-) | / | / | / | OR | 1 | Pelvis | NP | Died (3) |
China Case 11 | 11 | 52 | AP | II b | 12 | 14 | / | < 5% | / | / | / | / | / | / | / | / | / | / | / | / | BAO+IAP | 16 | Pelvis | CT | Alive with tumor (34) |
China Case 12 | 12 | 48 | NP | I a | 8 | 3~4 | (-) | < 5% | (+) | / | (-) | (-) | / | (-) | / | / | (-) | / | / | / | BAO+IAP | NP | NP | NP | TF (45) |
China Case 13 | 13 | 61 | AP | III b | 15 | 18 | / | 60% | (+) | / | (+) | (-) | (-) | (-) | / | / | (+) | / | / | / | OR | 2 | Pelvis | NP | Died (11) |
Lee et al. [17] | 14 | 69 | VB | I | 6 | 6~8 | / | > 10% | / | / | / | / | / | / | / | / | (+) | / | / | / | BAO | / | / | / | / |
Kruger et al. [18] | 15 | 32 | NP | I | 7 | 8 | / | 5%-10% | / | / | / | (-) | (-) | (-) | / | (-) | / | / | / | 116.1 | OR | NP | NP | NP | TF (12) |
Choi et al. [19] | 16 | 44 | AP | I a | 18 | 17 | / | < 1% | (+) | / | (-) | / | / | (-) | / | / | / | (-) | (-) | / | BAO+AP | NP | NP | NP | TF (120) |
17 | 34 | AP | I b | 13 | 8 | / | 20% | (+) | / | (-) | / | / | (-) | / | / | / | (+) | (+) | 26.5 | BAO+(VP16+IP) | NP | NP | NP | TF (60) | |
Testa et al. [20] | 18 | 44 | NP | III b | / | 7 | / | (+) | / | / | / | / | / | / | / | (+) | / | / | / | BAO+IA | NP | NP | NP | TF (50) | |
19 | 50 | NP | I a | / | 5~7 | / | 12% | (+) | / | / | / | / | / | / | / | (+) | / | / | / | BAO | NP | NP | NP | TF (5) | |
Jimenez et al. [21] | 20 | 55 | VB | I c | 23 | < 1-2 | / | 60% | (+) | (-) | (-) | / | / | / | / | / | / | / | / | / | BAO+IA | 14 | Liver | SS | Alive with tumor (14) |
Celyk et al. [5] | 21 | 49 | AP | III c | 12 | ≥ 4 | / | ? | (+) | / | / | (+) | / | (+) | / | / | / | / | / | 300 | BAO+TP | 36 | Pelvis, liver | NP | Died (42) |
McCluggage et al. [22] | 22 | 61 | AP | III c | 7 | 12~15 | / | / | (+) | / | (-) | (-) | / | (-) | / | / | (+) | / | / | 196 | BAO+CT | / | / | / | / |
Prat et al. [2] | 23 | 61 | / | I a | 10 | 4 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | BAO+RT | 18 | Liver | NP | Died (18) |
24 | 59 | / | II b | / | 8 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | BAO | 1 | Sigmoid | SS+RT | Died (4) | |
25 | 42 | / | II b | / | 25 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | BAO | 1 | Ureter | RT | Alive with tumor (13) | |
26 | 65 | / | I a | / | 10 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | OR | 6 | Pelvis | NP | Died (13) | |
27 | 73 | / | III | 6 | 7 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | CT | 2 | Pelvis, Peritoneum | CT | Died (2) | |
28 | 49 | / | I a | / | 5 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | BAO | 44 | Pelvis, Peritoneum | CT | Died (48) | |
Fukuda et al. [23] | 29 | 54 | AP | I a | 22 | 3~6 | / | 5.4%-8.2% | (+) | / | (-) | (-) | (-) | (-) | / | (+) | (+) | / | / | / | OR | 14 | Pelvis | SS+AP | TF (22) |
Iiboshi et al. [24] | 30 | 38 | NP | I a | 5.2 | 20~25 | / | / | (+) | / | (-) | / | (-) | (-) | / | / | / | / | / | / | OR | NP | NP | NP | TF (24) |
Watanabe et al. [25] | 31 | 44 | NP | IV | 12 | < 4 | / | / | (+) | / | (+) | (-) | (-) | (-) | (-) | / | / | / | / | / | OR+RT | / | / | / | Died (4) |